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Evidence, particularly practice-based evidence, is needed to guide
public health practice. With the goal of contributing to practice-
based evidence, the Division for Heart Disease and Stroke Preven-
tion at the Centers for Disease Control and Prevention combined
and streamlined aspects of an evaluability assessment and an ef-
fectiveness evaluation to create the Enhanced Evaluability Assess-
ment (EEA). This approach offers a viable and less costly alternat-
ive to evaluators and practitioners by quickly identifying and eval-
uating models with evidence of effectiveness that can be replic-
ated and expanded. The EEA can be applied to a range of public
health topics, not just cardiovascular health. This article provides a
step-by-step description of the EEA.
Introduction
Public health agencies often face substantial fiscal constraints and
challenges to identifying and implementing strategies that have the
greatest effect on improving health. Given this reality, there is an
increased need for efficient methods to identify programs or inter-
ventions with demonstrated evidence of effectiveness (1) that can
be replicated and expanded.  Three categories  of  evidence can
guide public health practice, one of which is practice-based evid-
ence (2). Practice-based evidence can be obtained by conducting
formal evaluation of practices being implemented by public health
practitioners (3) in a natural setting.
With the goal of contributing to practice-based evidence, the Divi-
sion for Heart  Disease and Stroke Prevention (DHDSP) at  the
Centers for Disease Control and Prevention (CDC) used a staged
evaluation approach — a pre-evaluation assessment to appraise a
program’s capacity and readiness for an effectiveness evaluation
and then an effectiveness  evaluation of  the selected site.  This
staged approach guides subsequent investment of resources in
evaluating public health practices and serves as a platform for de-
veloping  strong  evaluation  designs  for  programs  in  the  field,
thereby yielding practice-based evidence.
We describe a newly created evaluation approach, the Enhanced
Evaluability Assessment (EEA), which incorporates key aspects of
the staged approach while streamlining and truncating the process
to provide a quicker assessment of readiness,  an effectiveness
evaluation, and dissemination of practice-based evidence. This ap-
proach may improve informed decision making and lead to en-
hanced evaluation and implementation of public health programs.
This approach can be applied to all areas of public health inquiry,
not simply cardiovascular health. We describe each step of the
EEA approach, including considerations and lessons learned.
Expanding Practice-Based Evidence
Since 2008, DHDSP has used pre-evaluation assessments — the
Systematic Screening and Assessment (SSA) and the Evaluability
Assessment  (EA) — to  determine whether  a  program demon-
strates potential promise to address cardiovascular disease out-
comes. The SSA verifies that the intervention is 1) fully imple-
mented, 2) operating as intended, 3) operating consistently over
time, 4) capable of collecting and extracting data on outcomes, and
5) achieving its desired effects, according to the data (2). Leviton
and Gutman (4) assert that the SSA process is an efficient method
of sifting through many promising interventions, and the EA pro-
cess developed by Wholey (5) provides information through meth-
ods such as site visits and document review to identify whether a
program is evaluable. Both of these methods stop short of rigor-
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ously evaluating the program to assess effectiveness. For DHDSP,
the SSA and EA lasted approximately 12 months. Once a pro-
gram was selected and deemed evaluable and ready for an effect-
iveness  evaluation,  a  30-month  effectiveness  evaluation  was
launched to determine the intervention’s implementation effective-
ness relative to improved health outcomes. The effectiveness eval-
uation was a rigorous process that included interviews and quantit-
ative data abstraction and analyses to describe the core compon-
ents of the program, determine changes in health outcomes, and
provide recommendations for replication.
Although this multi-staged approach was fruitful, the timeframe of
approximately 42 months was often deemed too long, especially
given the shortage of evidence, limited resources, and a pressing
need for public health action. There is considerable interest among
public health practitioners and stakeholders to arrive at results
more quickly without sacrificing scientific rigor. Several methodo-
logic advances have been made that move rapid evaluation ap-
proaches from shortcuts to legitimate approaches (6), such as rap-
id assessments (7), rapid-cycle evaluation (8), and rapid-feedback
evaluations (9). DHDSP asked questions to determine whether
there was a viable alternative and what would be needed for a new
method. These questions were:
How much information is enough? When implementing the ini-
tial SSA and effectiveness evaluation model, it was clear that
the SSA did not yield enough information to determine effect-
iveness or guide replication in the field, which were determined
to be the most important necessities of adding to practice-based
evidence. Therefore, collecting information to meet these goals
was prioritized when developing a new method.
•
How do we identify evaluable programs quickly and
efficiently? Because DHDSP works with many partners, the
idea of using these partnerships to both gain an understanding
of areas of need related to practice-based evidence and identify
potentially evaluable programs was explored. This action would
shorten the time spent during the SSA nomination process sub-
stantially.
•
What is an acceptable level of rigor? When conducting the SSA,
EA, and effectiveness evaluation together, evaluators were able
to collect data over an extended period. Therefore, evaluators
could provide technical assistance to sites to help with data
quality, account for programmatic changes, and collect data at
different points to identify changes in outcomes over the project
period. With a shorter timeline, the sites would need to have
quality, retrospective data available to provide to evaluators.
•
After  brainstorming  answers  to  these  questions,  DHDSP  de-
veloped the framework for the EEA (Figure). Using this method,
DHDSP would identify interventions ready for evaluation, de-
scribe the core components, and show the effectiveness of innov-
ative interventions to increase replication while meeting the needs
of internal and external stakeholders to have an efficient and short-
er timeframe.
Figure. Conceptual model of the Enhanced Evaluability Assessment. 
Key Differences Between the EEA and
the SSA, EA, and Effectiveness
Evaluations
The EEA brings together key features of the SSA, EA, and effect-
iveness evaluation methods, with key modifications.
Identification of evaluable programs. The identification of evalu-
able programs had previously occurred through an SSA nomina-
tion process (4). The SSA call for nominations was open to state
and local health departments, health care providers, and other en-
tities working to reduce cardiovascular disease, whether receiving
CDC funding or not.  Under the EEA, the review of promising
practices in the field is done by in-house staff only. The pool of
programs includes state and local health departments or health
care  providers  — programs  either  funded  by  CDC or  simply
known to CDC through partners or from previous assessments.
Once identified, prospective programs were contacted to discern
their fit for an effectiveness evaluation. The EEA still incorpor-
ates the SSA method of using a set of criteria but eliminates the
sometimes long process (ie, 3–6 months) of collecting program
nominations and then coordinating and conducting an external
panel review to assess the nominations. Although this streamlined
approach makes the selection process more efficient, the pool of
potential nominated programs may be more limited than if there
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were a self-nomination process from the field.  However,  after
careful consideration, it was determined that this portion of the as-
sessment process could be shortened with minimum sacrifice giv-
en the broad networks in-house staff have.
Program description. Creating a comprehensive program descrip-
tion, including an accurate logic model, is an important part of the
EEA process. This component is similar to the EA process except
that it takes less time (3 months compared with 6 months), be-
cause the effort relies on telephone calls and sharing existing doc-
uments rather than making a site visit.
Effectiveness evaluation. The EEA uses a mixed-methods evalu-
ation approach, similar to the previously used method, but relies
more on existing data and a shorter timeframe than the 30-month
effectiveness evaluation.
Expert panel. Under the SSA and EA, expert panels are instru-
mental in 1) the initial selection of the site to undergo an EA and
2) determining the site’s suitability for evaluation after the EA.
Expert  panels  include  people  with  diverse  yet  relevant  back-
grounds and experiences to ensure that multiple perspectives are
represented. DHDSP selects subject matter experts from clinical,
academic, state, and local practice settings; CDC; and other feder-
al agencies. The EEA uses an internal expert panel at the end of
the evaluation period to determine the intervention’s public health
impact and the quality of the evidence (1).
Step-by-Step Description of the EEA
Approach
The EEA has several steps that start with the selection of the pro-
gram and end with an expert panel review followed by dissemina-
tion. The Box provides the timeframe for the 20-month project.
Box. Steps of the Enhanced Evaluability Assessment
Step Month Number(s)
Selection of program to evaluate 1–3





Preliminary results shared with program 18
Report writing 18–19
Final briefing with program 19
Step Month Number(s)
Expert panel convened 20
Dissemination 20
1. Selection of program to evaluate. A review of promising prac-
tices in the field is done by in-house CDC staff members. DHDSP
relies on CDC project officers, evaluation liaisons, or other CDC
staff who work with programs and have strong ties to state and na-
tional public health networks. A list of potential programs, includ-
ing both CDC-funded and non–CDC-funded, are assessed by us-
ing a set of criteria (ie, potential impact, health effect size, reach,
feasibility, sustainability, transferability, and data capacity). Once
the list is compiled, prospective programs are contacted by CDC
to discern their fit for an effectiveness evaluation. The point of
contact and key staff at the potential site are asked to provide rel-
evant  program  documents  and  verification  of  access  to  data
sources needed for the evaluation. It is essential that the selected
program have access to at least 6 months of data, that these data
are accessible to the program, and that the intervention itself is
well-established. The EEA approach can be applied to a range of
program interventions. The intervention drives the need for the
type of data; for example, the data could be health outcome data or
behavior change outcomes.
The selected program is involved in the entire EEA process and
has regular (usually twice monthly) meetings or calls with the
evaluators to discuss progress and provide input into the project.
Having a champion and single point of contact at the site is critic-
al to successfully conducting the EEA and obtaining the requested
data in a short timeframe. It is estimated that site staff engage-
ment in the EEA process is approximately 6 hours per week. This
level of engagement is slightly less than the anticipated engage-
ment for an effectiveness evaluation, which is approximately 10
hours per week.
2. Evaluation questions and evaluation design. The selected site is
substantially involved in the evaluation planning and implementa-
tion process. Once the site has agreed to participate in the EEA,
the next step is to engage the selected site in an in-depth discus-
sion of their evaluation needs and determine a mutually satisfying
focus for the EEA. It is important that the evaluation be value-ad-
ded for the site, because little compensation is being given to the
selected site to participate in the evaluation.
3. Data collection. Data for the EEA are collected through docu-
ment review, site visit, interviews, and quantitative data abstrac-
tion. The evaluators obtain existing program documents, reports,
and intervention descriptions to prepare a comprehensive program
description including an accurate logic model. This information is
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obtained by working with a point of contact at the site of the selec-
ted program. After a thorough review of this information, a site
visit is scheduled.
The purpose of the site visit is to conduct interviews of key per-
sonnel and partners involved in program implementation. Inter-
views and focus groups are conducted as needed, and site visitors
are given an opportunity to observe the program firsthand. This is
also the time when the evaluators can get  clarification on any
lingering questions that arise during the earlier review of written
materials.  In addition to the document review and site  visit,  a
quantitative data abstraction is completed.
Evaluators work with the program to abstract relevant data to be
used as evidence of promise or effectiveness in the strategies be-
ing implemented. In many cases, a modest stipend is given to the
selected program to secure the requested health outcome or imple-
mentation data. Once the initial program description is completed,
based on the document review, site visit, and other data collection,
the information is shared with the program to determine whether
there are any clarifications or misunderstandings that need to be
resolved.
4. Data analysis. The data collection for an EEA is a rigorous pro-
cess that uses both quantitative and qualitative methods. There-
fore, the analysis portion of the study includes a review of docu-
ments and identification of themes and a statistical analysis of the
quantitative data collected. The analyses vary based on the needs
of the study but always include triangulating the data and gaining
consensus of all reviewers.
5. Preliminary results shared with program. A key discussion point
occurs with the program after the analysis of process and outcome
data. These preliminary findings are presented to the program,
usually through a conference call or in webinar format, so that
they can be reviewed carefully and discussed as a group. Any po-
tential contradictions or areas that need follow up or clarification
are identified through this step before final reports are written and
findings are further disseminated. Any changes are then incorpor-
ated into the reports.
6. Report  writing.  Two reports  are written that  summarize the
findings of the evaluation. The first report, the program descrip-
tion, is usually written midway through the evaluation project and
provides a detailed description of the program and key findings
from the qualitative data collection. This report includes the goals
and expected outcomes of the program, the core components of
the program, factors affecting program implementation, and the lo-
gic model of the program. The second report incorporates much of
the program description report but focuses on the final results of
all data collection and analyses. Specific elements of the report in-
clude a brief executive summary that can be used as a stand-alone
document, a background section, an overview of the study design
and methods, results,  and a conclusion with recommendations.
The overview of the evaluation design and methods describes the
components, design, and evaluation questions; outlines the qualit-
ative and quantitative methods; and addresses study and data limit-
ations. The bulk of this report is the results section. The results be-
gin with information from the program description report, then a
discussion of implementation effectiveness, practice and program
related outcomes (including program reach), and program effect-
iveness. Program effectiveness results generally include health
system outcomes and clinical and patient-level outcomes of in-
terest in the evaluation. The conclusion provides a discussion of
the findings and considerations for replication. The considerations
for replication also link to the original selection criteria so that the
program can be assessed by an expert panel using those criteria.
7. Final briefing with program. A formal final briefing is provided
to the program in webinar format. The presentation includes an
overview of the evaluation methods, process and outcome evalu-
ation findings, final conclusions, and reflections on the evaluation.
Staff from the program who were not directly involved in the eval-
uation study are invited to participate to share thoughts related to
the evaluation methods, findings, and future implications. Clarific-
ations and refinements are made to the final report based on this
discussion.
8. Expert panel convened. A unique aspect of the EEA is the use
of an expert panel at the end of the evaluation to assess the inter-
vention using a  CDC-created  conceptual  framework (1).  Two
components of the framework are public health impact and qual-
ity of the evidence. Public health impact consists of 5 elements —
effectiveness, reach, feasibility, sustainability, and transferability.
Quality of evidence consists of 4 levels — weak, moderate, strong,
and rigorous. Experts receive a scoring matrix that has key con-
cepts defined and has questions to inform the assessment process.
Individuals with senior-level expertise in the areas of evaluation,
chronic disease public health, or best practices are identified and
invited to participate on the expert panel. Invitees may be internal
or external to CDC. The invitation for participation includes a
statement on the level of commitment (a total of 8 hours to review
the materials, make the assessment, and participate in the conven-
ing call or meeting), the estimated timeframe for reviewing the
materials and completing the scoring process, and a tentative date
for convening the panel in a small-group discussion format (in-
person or virtual). A statement related to compensation can be in-
cluded if panel members are external to CDC or do not represent
other federal agencies.
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To prepare the panel for the small-group discussion, a description
of the intervention, outcomes, literature related to the intervention,
instructions  for  reviewing  materials,  and  a  scoring  sheet  are
emailed in advance for submitting scoring sheets to CDC. Scores
are tallied, and overall comments are compiled. Summaries are
shared during the small group discussion in PowerPoint presenta-
tion format. The goal of convening the small group is to provide
panel members the opportunity to discuss assessments, engage in
dialogue,  and explore  content  related to  the  level  of  evidence
based on the public health impact determination and quality of
evidence provided. A CDC representative convenes the panel, fa-
cilitates the discussion, and clarifies points as needed. Input from
the expert panel is incorporated into the final evaluation docu-
ments.
9. Dissemination. In collaboration with the program, findings from
the evaluation are shared internally with the program and CDC
and shared externally on the websites of both the program and
CDC. Implementation guides, field notes, or other briefing docu-
ments may also be created to enable replication by other programs.
Whenever possible, the evaluation findings are also disseminated
through peer-reviewed journals and professional conferences.
Conclusion
To build practice-based evidence, appropriately designed evalu-
ation methods must be implemented with rigor and efficiency. As
a new methodology, the EEA incorporates these essential qualit-
ies by collecting primary and secondary data while reducing costs
and time. With one EEA completed and 2 others under way, early
indications suggest  that  this  approach offers  a  viable  and less
costly alternative to evaluators and practitioners by quickly identi-
fying and evaluating models with evidence of effectiveness that
can be replicated and expanded.
As with every methodology, there are some challenges and les-
sons learned that should be considered when determining whether
to  implement  an EEA versus  other  evaluation approaches.  As
noted, the pool of nominations may be smaller than the broader
call for nominations used by the SSA, which may inadvertently
omit some innovative or promising practices. Also, an approach
with a broader call for nominations may be more appropriate when
the focus area is new or emerging or when the evaluator does not
have access to networks to identify potentially promising pro-
grams. It is also essential with the EEA that the evaluators estab-
lish a strong relationship with the site at the beginning of the pro-
cess for the evaluation to be successful. It is important to consider
the evaluation needs of the program and to offer feedback and re-
ports that are useful to the program for program improvement,
building evaluation capacity, and demonstrating successes in ways
that are relevant for their stakeholders. DHDSP has found this to
be a key incentive for programs’ participation and ongoing en-
gagement. Another lesson learned is that it is critical during the
initial discussions with potential programs to understand what data
are collected or are accessible and how these data are managed
and extracted. Using the expert panel at the end of the evaluation
is a unique aspect of the EEA. Because DHDSP is using criteria
from the CDC framework, it is necessary for the summaries of the
findings to speak clearly to these criteria or it is difficult for the
panel to assess during the scoring process. Depending on the needs
of the evaluation and the focus of the program’s intervention, eval-
uators may wish to explore other frameworks or assessment criter-
ia for the expert panel to use.
Keeping these early lessons learned in mind will help evaluators
determine whether the EEA is a viable evaluation approach for
their work. Highlighting this approach is intended to increase eval-
uation capacity, support informed decision making, and lead to
improved evaluation and implementation of public health pro-
grams. Because the EEA is responsive to stakeholder needs and
enables the timely dissemination of evaluation findings, the EEA
has the potential to have broad application for a range of public
health topics.
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